$NMRA News

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

Neumora Therapeutics Reported Favorable Preclinical Toxicology Results From NMRA-215, An Oral NLRP3 Inhibitor In Development For Obesity And Cardiometabolic Disease; Plans To Submit An IND Application In Q4 Of 2026

RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5

Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation

Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy

Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data

Three pivotal MDD trial failures for Neumora lead to staffing cuts

Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5

HC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7

NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials

Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA)

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Neumora Therapeutics Says Navacaprant Did Not Achieve Primary Endpoint In KOASTAL-2 Or -3; Company To Discontinue Development Of Navacaprant

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Neumora Therapeutics Q1 EPS $(0.30) Beats $(0.33) Estimate